KeyBanc bullish on Evolent Health's strategy, starts stock with Overweight rating

On Friday, KeyBanc Capital Markets began coverage on shares of Evolent Health (NYSE:EVH), assigning an Overweight rating and setting a price target of $35.00. The firm's analyst highlighted the company's strategy and potential for long-term growth as key drivers for the positive outlook.

Evolent Health's recent pullback in share price was noted by KeyBanc as an opportunity, pointing to an attractive valuation at approximately 11 times forward EBITDA. The $35.00 price target is based on an 11 times multiple of the firm's estimated EBITDA for the year 2026, which is within Evolent Health's historical average range of 10 to 25 times.

According to KeyBanc, Evolent Health stands out as one of the most reasonably priced stocks they cover when considering growth-adjusted value. The firm expressed confidence in the company's business strategy and its ability to capitalize on its market position for future expansion.

The Overweight rating suggests that KeyBanc expects Evolent Health's stock to outperform the average return of the stocks the firm covers over the next 12 to 18 months. This initiation of coverage could signal to investors that Evolent Health is poised for a positive trajectory in the market.

Evolent Health's stock performance will continue to be observed by investors as the company progresses towards the growth and valuation targets outlined by KeyBanc. The firm's endorsement serves as a significant marker for Evolent Health's market potential and investor appeal.

In other recent news, Evolent Health has been the center of attention due to its strong financial performance and potential acquisition interest. The company has raised its full-year revenue guidance to between $2.56 billion and $2.6 billion and announced the strategic acquisition of Machinify Technology.

Analyst firms, including TD Cowen, Barclays, and Truist Securities, have maintained their positive ratings, with TD Cowen highlighting potential challenges associated with Humana Inc (NYSE:HUM).'s performance ratings and their possible impact on Evolent Health.

Despite these potential challenges, both Evolent Health's management and Barclays analysts see potential positive impacts, suggesting that Humana's need for cost management could drive demand for Evolent's services.

Furthermore, Evolent Health is reportedly exploring a potential sale following unsolicited acquisition interest. Analysts from Truist Securities and Barclays suggest that a private equity firm could potentially offer around $35 per share, with the possibility of a joint partnership between a strategic buyer and a private equity firm.

These are the recent developments in Evolent Health's operations and strategic planning. The company's Q3 revenue projections are between $615 million and $635 million, with an adjusted EBITDA between $60 million and $68 million.

InvestingPro Insights

Recent data from InvestingPro adds depth to KeyBanc's analysis of Evolent Health (NYSE:EVH). The company's revenue growth is noteworthy, with a 44.25% increase over the last twelve months as of Q2 2024, reaching $2.35 billion. This robust growth aligns with KeyBanc's positive outlook on the company's long-term potential.

InvestingPro Tips highlight that Evolent Health's stock price movements are quite volatile, which may explain the recent pullback noted by KeyBanc. However, the company has shown a strong return of 36.6% over the last three months, suggesting momentum that could support the Overweight rating.

While KeyBanc focuses on EBITDA multiples, it's worth noting that Evolent Health's P/E ratio (adjusted) stands at 149.78, indicating a high valuation relative to earnings. This could be justified by the expected growth, as another InvestingPro Tip reveals that net income is expected to grow this year.

For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide further insights into Evolent Health's financial position and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.